Stay updated on Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.

Latest updates to the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

- Check34 days agoChange DetectedUpdated to Revision: v3.1.0 with expanded contact details; old Revision: v3.0.2 removed.SummaryDifference0.1%

- Check49 days agoChange DetectedUpdated from v3.0.1 to v3.0.2; removed the 'Back to Top' element. No other substantive changes to core content, pricing, stock, or time-slot availability.SummaryDifference0.2%

- Check56 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.SummaryDifference0.2%

- Check63 days agoChange DetectedThe web page has updated its facility name and location details, including specific drug information and available locations in Beijing and Changchun, while removing several previous location references and cancer-related terms.SummaryDifference2%

- Check77 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.